60 Biggest Movers From Yesterday
Gainers
US Ecology, Inc. (NASDAQ: ECOL) shares surged 67.7% to close at $47.25 on Wednesday after Republic Services reported it will buy the company at $48 per share in cash.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Checkmate Pharmaceuticals Announces Initiation Of Patient Dosing In Phase 2 Multi-Indication Trial Using Vidutolimod
Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat
Checkmate Pharmaceuticals Q3 EPS $(0.69) Up From $(0.84) YoY
Checkmate Pharmaceuticals (NASDAQ:CMPI) reported quarterly losses of $(0.69) per share. This is a 17.86 percent increase over losses of $(0.84) per share from the same period last year.
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.
Checkmate Pharmaceuticals Announces Webcast On Innate Immune Modulators And Vidutolimod
- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to
Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target
Given the early clinical data on Checkmate Pharmaceuticals Inc’s (NASDAQ: CMPI) vidutolimod, key opinion leaders remain “positively biased on its outlook,” according to BofA Securities.
